Phase 2 N=12 ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Immunologic Deficiency Syndromes
Primary: Survival — 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
Primary: Objective Response Rate (ORR) — 0; 0 Participants
Phase 3 N=33 Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
Hemophilia B
Primary: Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay — 3.03 percentage of participants
Phase 2 N=61 Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Clear Cell Renal Carcinoma
Primary: Phase 1b: Maximum Safe Dose of Treatment Regimen — 15 mg/kg
N/A N=18 Assessing the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel
Asymptomatic Conditions
Primary: Small Bowel Water Content Measured by MRI — -5662; 3194; 10586 mL*min
Phase 1 N=22 Dolutegravir Pediatric Liquid Formulation Study
HIV Infections
Primary: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG — 11.9968; 13.7921; 12.1944 Hours*micrograms per…
N/A N=160 Controlled Attenuation Parameter (CAP) in Liver Allografts
Liver Transplant · Liver Steatosis · Liver Disease
Primary: Controlled Attenuation Parameter (CAP) - Accuracy — 220 dB/m
Phase 3 N=949 Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Macular Degeneration
Primary: Percentage of Participants With Stable Vision at Week 52 — 94.8; 91.3; 96.0 percentage of participants
Phase 2 N=134 Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
Pulmonary Embolism · Thrombotic Disease
Primary: Number of Participants Experiencing Adjudicated Clinically Relevant Bleeding Events Following Intravenous Infusion of DS-1040b or Placebo in Addition to Standard of Care…
Phase 4 N=40 GrafixPL PRIME Evaluation Case Study
Diabetic Foot Ulcer
Primary: Number of Participants With Complete Closure of the Index Ulcer — 19 Participants
Phase 2 N=200 Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
Alzheimer's Disease · Dementia · Memory Loss
Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67
N/A N=11 Ventilatory Support to Improve Exercise Training in High Level Spinal Cord Injury
Spinal Cord Injury
Primary: Change in Baseline Aerobic Capacity After 3 Months of FES-row Training. — 0.21; 0.08 L/min
N/A N=115 Study to Compare the Incidence of Biliary Complications After Liver Transplantation
Liver Transplant; Complications
Primary: Number of Participants With Biliary Complications — 19; 12 participants
Phase 2 N=20 A Study to Examine APL-130277 in Patients With Parkinson's Disease
Parkinson's Disease
Primary: The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 — 78.9; 31.6; 78.9; 68.4 percentage of participants
Phase 2 N=17 Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Tumor Induced Osteomalacia (TIO) · Epidermal Nevus Syndrome (ENS)
Primary: Percentage of Participants Achieving Mean Serum Phosphorus Levels Above 2.5 mg/dL at the Mid-Point of the Dose Intervals Between Baseline and Week 24 — 50.0 percentage…